Try our beta test site

Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction

This study has been terminated.
(Enrollment discontinued after second cohort completed.)
Information provided by:
Reata Pharmaceuticals, Inc. Identifier:
First received: October 26, 2007
Last updated: November 6, 2007
Last verified: November 2007
This study assesses the safety and tolerability of RTA 402 in patients with liver disease.

Condition Intervention Phase
Liver Disease
Drug: RTA 402
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 (CDDO-Me) Administered Orally for 14 Days in Patients With Hepatic Dysfunction

Resource links provided by NLM:

Further study details as provided by Reata Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • To evaluate the safety and tolerability of multiple-dose oral administration of RTA 402 in patients with hepatic dysfunction. [ Time Frame: 28 days ]

Secondary Outcome Measures:
  • To correlate the biological activity of RTA 402 with drug concentration in plasma. [ Time Frame: 28 days ]

Enrollment: 16
Study Start Date: April 2007
Study Completion Date: November 2007
Arms Assigned Interventions
Experimental: 1
RTA 402
Drug: RTA 402
5 mg oral capsules
Experimental: 2
RTA 402
Drug: RTA 402
25 mg oral capsules
Experimental: 3
RTA 402
Drug: RTA 402
50 mg oral capsules

Detailed Description:

RTA 402 is a synthetic triterpenoid that is designed to suppress oxidative stress and inflammatory processes that play a significant role in a wide variety of diseases. It is a potent suppressor of inflammation and oxidative stress. Oxidative stress plays a role in the pathogenesis of hepatitis, and RTA 402 has demonstrated activity in a preclinical model of hepatitis, in addition to other models of inflammation.

This is a 28-day, multiple-dose, dose-escalation study. It is anticipated that a total of 3 groups of 8 patients each will be enrolled, in which 6 patients in each group will be randomized to receive RTA 402, and 2 patients per group will be randomized to placebo (3:1). Patients will receive treatment daily for 14 days with a starting dose of 5mg, 25mg, or 50mg. Patients will return for follow up visits on Days 16 and 21, and complete end of study procedures on Day 28.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic liver disease.
  • An estimated creatinine clearance of ≥ 60 mL/min.
  • Serum alanine transaminase (ALT) or aspartate transaminase (AST) elevation must be above the upper limit of normal and below 5 times the upper limit of normal for patients with underlying liver disease; Child-Pugh score 5 to 9 (mild to moderate impairment).
  • Patient must agree to practice effective contraception during the entire study period.
  • Patient is willing to avoid strenuous physical activity from 24 hours prior to the study start, throughout the study, and for 2 weeks after the administration of the dose of study drug
  • Patient is willing to avoid any alcohol consumption for the 24 hours prior to, and the 48 hours after administration of study drug; and avoid excessive alcohol consumption for the duration of the follow-up period.
  • Patient must be able and willing to sign informed consent form.

Exclusion Criteria:

  • Patient with clinically significant illnesses or recent hospitalization (within 60 days) which could compromise participation in the study in the judgment of the investigator, including: uncontrolled diabetes; active or uncontrolled infection; Confirmed diagnosis of HIV infection; uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled cardiac arrhythmia.
  • Patient with any other auto immune disease, major chronic inflammatory disease or syndrome requiring significant treatment within the past year.
  • Patients who are pregnant or breast feeding
  • Patient receiving or has received any investigational drug within 30 days prior (or is currently using an investigational device)
  • Patients with prior (within 4 weeks) or concurrent treatment with oral steroids, or protein-based therapy (i.e. TNFa)
  • Patients with positive urine screen for drugs of abuse except when receiving a prescribed medication for a known indication
  • Patients with Grade 2 or above hepatic encephalopathy.
  • Patients who donated blood or experienced a significant blood loss (>450 mL) within 8 weeks of screening
  • Patients with a history of bleeding varices within 12 weeks of screening.
  • Patients with psychiatric illness or other condition that would limit compliance with study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00550849

United States, Florida
Orlando Clinical Research Center
Orlando, Florida, United States, 32809
Sponsors and Collaborators
Reata Pharmaceuticals, Inc.
Principal Investigator: Thomas C. Marbury, MD Orlando Clinical Research Center
  More Information Identifier: NCT00550849     History of Changes
Other Study ID Numbers: RTA 402-C-0701
Study First Received: October 26, 2007
Last Updated: November 6, 2007

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases processed this record on March 30, 2017